What Is Meloxicam Prescribed For: Uses & Risks

Meloxicam is a prescription nonsteroidal anti-inflammatory drug (NSAID) used primarily to treat pain, swelling, and stiffness caused by arthritis. Its approved uses in the United States include osteoarthritis, rheumatoid arthritis, and juvenile idiopathic arthritis in children, but doctors also prescribe it for other inflammatory conditions and, increasingly, for post-operative pain management. What sets meloxicam apart from older over-the-counter NSAIDs is its preferential activity on a specific enzyme involved in inflammation, which gives it a somewhat gentler profile on the stomach while still carrying the cardiovascular warnings common to the entire drug class.

How Meloxicam Works

All NSAIDs reduce pain and inflammation by blocking cyclooxygenase (COX) enzymes, which are involved in producing prostaglandins. Your body has two main versions of this enzyme. COX-1 is active all the time, helping protect the stomach lining, supporting kidney function, and assisting with blood clotting. COX-2, on the other hand, ramps up specifically during inflammation. Most traditional NSAIDs block both enzymes without much discrimination, which is why drugs like ibuprofen and naproxen can irritate the stomach.

Meloxicam preferentially targets COX-2, meaning it dials down inflammation while interfering less with the protective prostaglandins controlled by COX-1.¹ In volunteer studies, a standard dose of meloxicam did not significantly inhibit COX-1-driven effects like kidney prostaglandin production or platelet clumping, whereas the older NSAID indomethacin clearly did.² That selectivity is not absolute — at higher doses, meloxicam still affects COX-1 to some degree — but it is enough to make a clinically meaningful difference in side-effect rates, particularly in the gut.

Osteoarthritis

Osteoarthritis is the most common reason you will see meloxicam prescribed. It is the wear-and-tear form of arthritis that develops as joint cartilage gradually breaks down, causing pain, stiffness, and reduced mobility, especially in the knees, hips, and hands. In a placebo-controlled trial of knee osteoarthritis, both the 7.5 mg and 15 mg daily doses of meloxicam significantly reduced pain during movement, and patients and investigators rated its overall effectiveness well above placebo.³

The practical question for most people is how meloxicam stacks up against the NSAIDs they already know. In a six-month head-to-head trial against diclofenac (a widely used prescription NSAID), meloxicam at 7.5 mg daily provided similar improvements in overall pain, movement pain, and quality of life, with a trend toward fewer side effects.⁴ Similar findings have emerged in comparisons with naproxen and piroxicam.⁵ In short, meloxicam is not a stronger painkiller than the alternatives; it is roughly equivalent, with its advantage lying mainly in tolerability.

Rheumatoid Arthritis and Juvenile Idiopathic Arthritis

Rheumatoid arthritis is a different beast from osteoarthritis. It is an autoimmune condition where the immune system attacks the joint lining, causing chronic inflammation that can eventually damage bone and cartilage. Meloxicam does not slow the progression of the disease — that job belongs to disease-modifying drugs — but it helps control the day-to-day pain and swelling. A six-month trial comparing meloxicam 7.5 mg to naproxen 750 mg daily in rheumatoid arthritis patients found comparable improvements in painful and swollen joints, global efficacy scores, and most secondary measures.⁶

Meloxicam is also one of the few NSAIDs studied and approved specifically for children with juvenile idiopathic arthritis (JIA), a group of conditions that cause persistent joint inflammation in kids under 16. In a randomized trial, meloxicam oral suspension showed short- and long-term safety and effectiveness comparable to naproxen suspension in children with JIA.⁷ Having a liquid formulation makes dosing easier for younger patients who cannot swallow tablets reliably.

Uses Beyond the Label

Doctors frequently prescribe meloxicam for inflammatory conditions outside its formal approvals. Ankylosing spondylitis, a chronic inflammatory disease of the spine that causes fusion of vertebrae over time, is one of the most common off-label applications. NSAIDs are considered first-line therapy for this condition, and meloxicam has been included in network meta-analyses comparing NSAID options for ankylosing spondylitis alongside drugs like celecoxib, etoricoxib, and diclofenac.⁸ Gout flares, tendinitis, bursitis, and general musculoskeletal pain are other scenarios where meloxicam shows up, though the prescribing in those cases is guided more by clinical experience than by large trials specific to meloxicam.

A newer and distinct use is post-operative pain control. An intravenous formulation of meloxicam (30 mg) has been developed specifically for hospital settings. Pooled data from phase II and III clinical trials showed that IV meloxicam was well tolerated and reduced post-surgical rescue opioid use compared to placebo.⁹ In a trial specifically focused on total knee replacement, patients receiving IV meloxicam used roughly a third less opioid medication in the first 24 hours after surgery compared to those given placebo.¹⁰ That opioid-sparing effect is a significant draw at a time when hospitals are actively trying to minimize narcotic exposure after surgery.¹¹

Gastrointestinal Side Effects

Stomach and intestinal problems are the most familiar risk of any NSAID, and the biggest selling point of meloxicam is that it appears to cause fewer of them. A meta-analysis and systematic review pooling data from randomized controlled trials found that patients taking meloxicam had about a third fewer gastrointestinal adverse events compared to those on non-selective NSAIDs. They experienced less dyspepsia, fewer serious ulcer-related complications, and were less likely to stop taking the drug because of gut symptoms.¹²

That said, “fewer” is not “none.” Meloxicam can still cause nausea, abdominal pain, diarrhea, and, less commonly, stomach ulcers or bleeding. The risk goes up with higher doses, longer duration of use, older age, a history of ulcers, and concurrent use of blood thinners or corticosteroids. The authors of that meta-analysis noted that most trials used the lower 7.5 mg dose of meloxicam, so the safety advantage may narrow somewhat at 15 mg. If you are at high risk for GI bleeding, your doctor may add a proton-pump inhibitor (a stomach acid reducer) alongside meloxicam, just as they would with any NSAID.

Cardiovascular Risks

After the withdrawal of rofecoxib (Vioxx) in 2004, all NSAIDs came under intense scrutiny for heart and blood vessel risks. Regulatory agencies now require a boxed warning on every prescription NSAID stating that the drug class can increase the chance of heart attack and stroke, and meloxicam is no exception. Clinical trials of both COX-2-selective and nonselective NSAIDs lasting up to three years have confirmed that increased risk.

Where meloxicam falls on the cardiovascular risk spectrum is a question researchers have been circling for years. A systematic review found that meloxicam carried a small but statistically real increase in overall cardiovascular risk, with the signal driven mainly by vascular events rather than heart attacks or kidney problems specifically.¹³ A separate population-based study estimated the risk of heart attack among current meloxicam users at roughly 38% higher than in people who had stopped using any NSAID, a figure comparable to diclofenac’s risk in the same analysis and somewhat higher than naproxen’s.¹⁴ One encouraging finding from that study: concurrent low-dose aspirin use appeared to eliminate the excess heart-attack risk in meloxicam users, though this should not be taken as blanket advice to combine the two, since doing so raises GI bleeding risk.

A nationwide emulated-trial study compared diclofenac’s cardiovascular event rates with those of meloxicam and other COX-2-selective drugs and found that diclofenac fared worse, with elevated rates compared to meloxicam.¹⁵ The bottom line is that meloxicam is not cardiovascular-risk-free, but among commonly prescribed NSAIDs, it sits in the middle of the pack rather than at the top. People with existing heart disease, uncontrolled high blood pressure, or a history of stroke should use it only when the benefits clearly outweigh the risks, and ideally at the lowest dose for the shortest time possible.

Kidney Concerns

All NSAIDs can impair kidney function because prostaglandins help maintain blood flow to the kidneys, especially when you are dehydrated, elderly, or already have compromised kidney function. Meloxicam’s COX-2 selectivity does not fully protect against this. The systematic review mentioned earlier found no statistically significant increase in renal risk with meloxicam overall, but case reports serve as a reminder that serious kidney injury can happen.¹³ One published case involved a 65-year-old woman who developed acute kidney injury and nephrotic syndrome after just three days on meloxicam 15 mg for tendinitis.¹⁶

This does not mean healthy kidneys are commonly at risk from a short course. It means that dehydration, pre-existing kidney disease, older age, heart failure, and concurrent use of other drugs that stress the kidneys (like certain blood-pressure medications or contrast dye) amplify the danger. If you are starting meloxicam for longer-term use, your doctor will likely check your kidney function with a simple blood test at baseline and periodically thereafter.

Important Drug Interactions

Meloxicam shares the drug-interaction profile common to NSAIDs, but a few combinations deserve special attention. The most clinically significant is the interaction with warfarin, the widely used blood thinner. A study examining risk factors for dangerous rises in INR (the measure of how thin your blood is) found that meloxicam use was an independent predictor of INR increases when combined with warfarin.¹⁷ A rising INR means your blood becomes dangerously slow to clot, increasing bleeding risk. If you take warfarin and your doctor adds meloxicam, expect more frequent INR monitoring.

Other interactions to be aware of include:

Blood pressure drugs: NSAIDs can blunt the effectiveness of ACE inhibitors, ARBs, and diuretics, potentially raising blood pressure and stressing the kidneys.
Lithium: NSAIDs reduce lithium clearance, which can push blood levels into the toxic range.
Methotrexate: At high doses, co-administration with NSAIDs can slow methotrexate elimination, increasing toxicity risk.
Alcohol: Combining NSAIDs with regular alcohol use compounds the risk of stomach bleeding.

These interactions apply to NSAIDs as a class, and a review of prescription and over-the-counter analgesic interactions confirmed well-documented evidence for each of them.¹⁸ The key takeaway is to tell every prescribing doctor and pharmacist about all of your medications, including over-the-counter pain relievers, before starting meloxicam.

Dosing and How the Body Handles Meloxicam

Meloxicam is typically prescribed as a once-daily oral tablet or liquid at either 7.5 mg or 15 mg for adults. One of the reasons once-daily dosing works is its long half-life. A pharmacokinetic study in rheumatoid arthritis patients found a terminal elimination half-life of roughly 20 hours, which means the drug lingers in the body long enough to maintain steady levels with a single daily dose. That same study found that age and sex both influenced how quickly the body cleared meloxicam, with older patients and women clearing it somewhat more slowly.¹⁹ In practice, this means older adults are more likely to accumulate the drug and may do better at the lower 7.5 mg dose.

In overdose situations, meloxicam’s long half-life becomes a liability because the drug stays in the system. Cholestyramine, a bile-acid-binding resin normally used for cholesterol, has been shown to speed up meloxicam elimination significantly, cutting the mean half-life from about 19.5 hours to 12.7 hours and reducing the drug’s residence time in the body by nearly 40%.²⁰ This works because meloxicam appears to undergo recirculation between the gut and the liver, and cholestyramine traps it in the intestine before it can be reabsorbed. Poison-control protocols for NSAID overdose can take advantage of this.

Meloxicam in Veterinary Medicine

If you have a dog with arthritis, there is a good chance your vet has prescribed meloxicam. It is one of the most widely used NSAIDs in veterinary practice and comes in a palatable liquid formulation that makes daily dosing straightforward. A clinical trial in dogs with chronic osteoarthritis showed significant reductions in lameness, stiffness, pain on rising, and exercise intolerance after four weeks of treatment, with minimal side effects.²¹ A comparator trial found that meloxicam performed similarly to mavacoxib, a longer-acting veterinary NSAID, with comparable efficacy and adverse-event rates.²²

The question of how long a dog should stay on meloxicam, and whether the dose can be gradually lowered, has been studied directly. In a trial where dogs were either maintained on their full dose or gradually stepped down, most dogs tolerated at least a modest dose reduction, but dogs in the reduction group were significantly more likely to drop out of the study due to worsening symptoms. The median point of dropout corresponded to about a 60% dose reduction, suggesting there is a meaningful floor below which the drug stops working adequately for many dogs.²³

Cats are a different story. While meloxicam has been used in feline medicine, there is growing concern about its association with acute kidney injury in cats, particularly when given by injection around the time of surgery.²⁴ Cats metabolize NSAIDs much more slowly than dogs, and their kidneys are more vulnerable. In the United States, only a single one-time injectable dose of meloxicam is approved for cats, and repeated dosing is strongly cautioned against. If your vet prescribes meloxicam for a cat, the dosing regimen will be very different from what a dog receives, and close monitoring is expected.

Who Should Not Take Meloxicam

Certain people should avoid meloxicam entirely. Anyone who has had an allergic reaction to aspirin or another NSAID — particularly reactions involving hives, facial swelling, or asthma-like breathing difficulty — should not take it. Meloxicam is also contraindicated in the setting of coronary artery bypass surgery; a boxed warning specifically prohibits NSAID use for pain management around that procedure because of sharply elevated cardiovascular risk.

People with active stomach or intestinal ulcers, severe kidney disease, severe liver disease, or uncontrolled heart failure fall into the avoid-or-use-extreme-caution category. Pregnant women should not use meloxicam in the third trimester because NSAIDs can cause premature closure of a fetal blood vessel (the ductus arteriosus), and recent FDA guidance extends caution to use after 20 weeks of pregnancy due to a risk of low amniotic fluid.

For everyone else, the general prescribing principle is the same one that applies to all NSAIDs: use the lowest effective dose for the shortest duration that manages your symptoms. If meloxicam at 7.5 mg controls your pain, there is no reason to go to 15 mg. If you only need it for a flare rather than daily, intermittent use reduces cumulative risk. And because the drug’s risks compound with age and with the number of other medications on board, an honest conversation with your doctor about the full list of things you are taking — including over-the-counter ibuprofen, aspirin, or supplements — is the most important safety step you can take.